| Year |
Citation |
Score |
| 2021 |
Saha T, Mondal J, Khiste S, Lusic H, Hu ZW, Jayabalan R, Hodgetts KJ, Jang H, Sengupta S, Eunice Lee S, Park Y, Lee LP, Goldman A. Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer. Nanophotonics. 10: 3063-3073. PMID 34589378 DOI: 10.1515/nanoph-2021-0142 |
0.355 |
|
| 2021 |
Dash C, Saha T, Sengupta S, Jang HL. Inhibition of Tunneling Nanotubes between Cancer Cell and the Endothelium Alters the Metastatic Phenotype. International Journal of Molecular Sciences. 22. PMID 34200503 DOI: 10.3390/ijms22116161 |
0.316 |
|
| 2020 |
Chung I, Zhou K, Barrows C, Banyard J, Wilson A, Rummel N, Mizokami A, Basu S, Sengupta P, Shaikh B, Sengupta S, Bielenberg DR, Zetter BR. Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer. Frontiers in Oncology. 10: 594141. PMID 33738243 DOI: 10.3389/fonc.2020.594141 |
0.643 |
|
| 2020 |
Smalley M, Natarajan SK, Mondal J, Goldman D, Shanthappa B, Pellowe M, Dash C, Saha T, Khiste S, Ramadurai N, Eton EO, Smalley JL, Brown A, Thayakumar A, Rahman M, ... ... Sengupta S, et al. Nano-Engineered Disruption of Heat shock protein 90 (Hsp90) Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. Cancer Research. PMID 33077554 DOI: 10.1158/0008-5472.CAN-19-4036 |
0.324 |
|
| 2020 |
Zhou X, Qu M, Tebon P, Jiang X, Wang C, Xue Y, Zhu J, Zhang S, Oklu R, Sengupta S, Sun W, Khademhosseini A. Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 7: 2001447. PMID 33042756 DOI: 10.1002/Advs.202001447 |
0.387 |
|
| 2020 |
Jolly MK, Sengupta S, Dai H, Jang H. Engineering Breast Cancer Mammospheres Using Vibration The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.09055 |
0.342 |
|
| 2019 |
Goldman A, Khiste S, Freinkman E, Dhawan A, Majumder B, Mondal J, Pinkerton AB, Eton E, Medhi R, Chandrasekar V, Rahman MM, Ichimura T, Gopinath KS, Majumder P, Kohandel M, ... Sengupta S, et al. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Science Signaling. 12. PMID 31431543 DOI: 10.1126/Scisignal.Aas8779 |
0.434 |
|
| 2019 |
Connor Y, Tekleab Y, Tekleab S, Nandakumar S, Bharat D, Sengupta S. A mathematical model of tumor-endothelial interactions in a 3D co-culture. Scientific Reports. 9: 8429. PMID 31182723 DOI: 10.1038/S41598-019-44713-2 |
0.374 |
|
| 2019 |
Bandaru P, Chu D, Sun W, Lasli S, Zhao C, Hou S, Zhang S, Ni J, Cefaloni G, Ahadian S, Dokmeci MR, Sengupta S, Lee J, Khademhosseini A. A Microfabricated Sandwiching Assay for Nanoliter and High-Throughput Biomarker Screening. Small (Weinheim An Der Bergstrasse, Germany). e1900300. PMID 30884183 DOI: 10.1002/Smll.201900300 |
0.328 |
|
| 2019 |
Sun W, Luo Z, Lee J, Kim HJ, Lee K, Tebon P, Feng Y, Dokmeci MR, Sengupta S, Khademhosseini A. Organ-on-a-Chip for Cancer and Immune Organs Modeling. Advanced Healthcare Materials. e1801363. PMID 30605261 DOI: 10.1002/Adhm.201801363 |
0.36 |
|
| 2019 |
Dash C, Saha T, Khiste S, Sengupta S. Abstract 4516: Suppression of metastasis by inhibiting nanoscale physical communication of cancer cell and the endothelium Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4516 |
0.37 |
|
| 2019 |
Saha T, Dash C, Khiste S, Sengupta S. Abstract 1480: A novel mechanism of immunosuppression via nanotube mediated mitochondrial trafficking between cancer cell and immune cell Cancer Research. 79: 1480-1480. DOI: 10.1158/1538-7445.Am2019-1480 |
0.425 |
|
| 2019 |
Sun W, Luo Z, Lee J, Kim H, Lee K, Tebon P, Feng Y, Dokmeci MR, Sengupta S, Khademhosseini A. Organ‐on‐a‐Chip: Organ‐on‐a‐Chip for Cancer and Immune Organs Modeling (Adv. Healthcare Mater. 4/2019) Advanced Healthcare Materials. 8. DOI: 10.1002/Adhm.201970014 |
0.323 |
|
| 2018 |
Kulkarni A, Chandrasekar V, Natarajan SK, Ramesh A, Pandey P, Nirgud J, Bhatnagar H, Ashok D, Ajay AK, Sengupta S. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nature Biomedical Engineering. 2: 589-599. PMID 30956894 DOI: 10.1038/S41551-018-0254-6 |
0.368 |
|
| 2018 |
Ghosh S, Sinha M, Bhattacharyya A, Sadhasivam S, Megha J, Reddy S, Saini S, Singh H, Kumar D, Kaur SP, Mishra M, Usharani D, Ghosh S, Sengupta S. A rationally designed multi-functional antibiotic for the treatment of drug-resistant acne. The Journal of Investigative Dermatology. PMID 29409921 DOI: 10.1016/J.Jid.2017.11.041 |
0.301 |
|
| 2018 |
Gupta N, Biswas G, Sengupta A, Roy M, Roy S, Sengupta S. Abstract 751: A controlled affinity-guided ADC-linker (MAGNET) technology Cancer Research. 78: 751-751. DOI: 10.1158/1538-7445.Am2018-751 |
0.31 |
|
| 2018 |
Khiste S, Eton E, Hodgetts K, Lusic H, Gopinath K, Krishnamurthy S, Sengupta S, Goldman A. Abstract 51: Role of hematopoietic cell kinase (HCK) in breast cancer dormancy Cancer Research. 78: 51-51. DOI: 10.1158/1538-7445.Am2018-51 |
0.482 |
|
| 2018 |
Sengupta A, Samarla M, Pandey M, Sarkar A, Roy M, Sengupta S. Abstract 4918: Pharmacokinetics and toxicity studies of AT1965, a B-cell activating immunotherapy Cancer Research. 78: 4918-4918. DOI: 10.1158/1538-7445.Am2018-4918 |
0.341 |
|
| 2018 |
Roy M, Krishna V, Sengupta A, Roy S, Kulkarni A, Sengupta S. Abstract 4712: AT1965, a novel B cell-activating immunotherapy, exerts potent anticancer activity Cancer Research. 78: 4712-4712. DOI: 10.1158/1538-7445.Am2018-4712 |
0.419 |
|
| 2018 |
Ghosh S, Sinha M, Sadhasivam S, Bhattacharyya A, Samanta R, Nandy A, Saini S, Mishra M, Sengupta S. 1108 Preclinical evaluation of a novel fluoroquinolone for its multi-dimensional therapeutic effects against drug-resistant Propionibacterium acnes induced acne Journal of Investigative Dermatology. 138. DOI: 10.1016/J.Jid.2018.03.1121 |
0.323 |
|
| 2017 |
Sengupta S. Cancer Nanomedicine: Lessons for Immuno-Oncology. Trends in Cancer. 3: 551-560. PMID 28780932 DOI: 10.1016/J.Trecan.2017.06.006 |
0.424 |
|
| 2017 |
Gupta N, Kancharla J, Kaushik S, Ansari A, Hossain S, Goyal R, Pandey M, Sivaccumar J, Hussain S, Sarkar A, Sengupta A, Mandal SK, Roy M, Sengupta S. Development of a facile antibody-drug conjugate platform for increased stability and homogeneity. Chemical Science. 8: 2387-2395. PMID 28451344 DOI: 10.1039/C6Sc05149A |
0.319 |
|
| 2017 |
Goldman A, Majumder B, Dhawan A, Kohandel M, Majumder P, Sengupta S. Abstract P3-03-18: An ex-vivo platform predicts anti-tumor outcome of metabolically-targeted, algorithm-driven combination therapy in triple-negative breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-18 |
0.485 |
|
| 2017 |
Ismail N, Kulkarni A, Kumar S, krishna V, Sengupta S. Abstract 4610: Towards understanding the cellular uptake patterns of nano-particles among different immune cell lines Cancer Research. 77: 4610-4610. DOI: 10.1158/1538-7445.Am2017-4610 |
0.39 |
|
| 2016 |
Calibasi Kocal G, Güven S, Foygel K, Goldman A, Chen P, Sengupta S, Paulmurugan R, Baskin Y, Demirci U. Dynamic Microenvironment Induces Phenotypic Plasticity of Esophageal Cancer Cells Under Flow. Scientific Reports. 6: 38221. PMID 27910892 DOI: 10.1038/Srep38221 |
0.413 |
|
| 2016 |
Kulkarni A, Natarajan SK, Chandrasekar V, Pandey PR, Sengupta S. Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anti-Cancer Efficacy. Acs Nano. PMID 27656909 DOI: 10.1021/Acsnano.6B01600 |
0.432 |
|
| 2016 |
Sengupta S, Mantha AK, Song H, Roychoudhury S, Nath S, Ray S, Bhakat KK. Elevated level of acetylation of APE1 in tumor cells modulates DNA damage repair. Oncotarget. PMID 27655688 DOI: 10.18632/Oncotarget.12113 |
0.326 |
|
| 2016 |
Kulkarni A, Pandey P, Rao P, Mahmoud A, Goldman A, Sabbisetti V, Parcha S, Natarajan SK, Chandrasekar V, Dinulescu D, Roy S, Sengupta S. Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anti-Cancer Efficacy. Acs Nano. PMID 27452234 DOI: 10.1021/Acsnano.6B00241 |
0.366 |
|
| 2016 |
Molavian HR, Goldman A, Phipps CJ, Kohandel M, Wouters BG, Sengupta S, Sivaloganathan S. Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects. Scientific Reports. 6: 27439. PMID 27278439 DOI: 10.1038/Srep27439 |
0.372 |
|
| 2016 |
Goldman A, Kulkarni A, Kohandel M, Pandey P, Rao P, Natarajan SK, Sabbisetti V, Sengupta S. Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. Acs Nano. PMID 27257911 DOI: 10.1021/Acsnano.6B00320 |
0.507 |
|
| 2016 |
Boareto M, Jolly MK, Goldman A, Pietilä M, Mani SA, Sengupta S, Ben-Jacob E, Levine H, Onuchic JN. Notch-Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype. Journal of the Royal Society, Interface / the Royal Society. 13. PMID 27170649 DOI: 10.1098/Rsif.2015.1106 |
0.302 |
|
| 2016 |
Kulkarni AA, Vijaykumar VE, Natarajan SK, Sengupta S, Sabbisetti VS. Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 27084552 DOI: 10.1016/J.Nano.2016.04.002 |
0.434 |
|
| 2016 |
Kulkarni A, Rao P, Natarajan S, Goldman A, Sabbisetti VS, Khater Y, Korimerla N, Chandrasekar V, Mashelkar RA, Sengupta S. Reporter nanoparticle that monitors its anticancer efficacy in real time. Proceedings of the National Academy of Sciences of the United States of America. PMID 27036008 DOI: 10.1073/Pnas.1603455113 |
0.411 |
|
| 2016 |
Bhakat KK, Sengupta S, Adeniyi VF, Roychoudhury S, Nath S, Bellot LJ, Feng D, Mantha AK, Sinha M, Qiu S, Luxon BA. Regulation of limited N-terminal proteolysis of APE1 in tumor via acetylation and its role in cell proliferation. Oncotarget. PMID 26981776 DOI: 10.18632/Oncotarget.8026 |
0.356 |
|
| 2016 |
Goldman A, Dhawan A, Medhi R, Kohandel M, Sengupta S. Abstract A58: Temporal dynamics underpin metabolism-driven cancer therapy cross-resistance Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A58 |
0.43 |
|
| 2016 |
Majumder P, Majumder B, Mehrotra D, Radhakrishnan P, Baraneedharan U, Agarwal S, Sengupta S, Babu G. Abstract P5-08-42: Development and validation of personalized ex vivo platform mimicking patient heterogeneous tumor microenvironment to enable personalized treatment for breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-08-42 |
0.409 |
|
| 2016 |
Sengupta A, Roy M, Sarkar A, Mylavarapu S, Modi S, Gupta N, Hossain S, Ansari A, Pandey M, Yadav Y, Sengupta S. Abstract P5-03-03: Designing a novel platinum chemotherapeutic (IO-125) for treatment of breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-03-03 |
0.447 |
|
| 2016 |
Chandrasekar V, Natarajan SK, Sengupta S, Kulkarni A. Abstract LB-059: Supramolecular fusion nanotherapeutic mediated synergistic inhibition of PI3K and MEK pathways Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-059 |
0.479 |
|
| 2016 |
Mylavarapu S, Kaushik S, Yadav Y, Roy M, Sengupta A, Sengupta S. Abstract 2231: IO125 is a potent inducer of tumor immunogenicity Cancer Research. 76: 2231-2231. DOI: 10.1158/1538-7445.Am2016-2231 |
0.435 |
|
| 2015 |
Mylavarapu S, Kumari S, Hossain S, B H, Gupta N, Sarkar A, Ansari A, Velpandian T, Roy M, Sengupta S. IO-125: A novel supramolecular platinum chemotherapy for triple negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 153. PMID 28147743 DOI: 10.1200/Jco.2015.33.28_Suppl.153 |
0.417 |
|
| 2015 |
Connor Y, Tekleab S, Nandakumar S, Walls C, Tekleab Y, Husain A, Gadish O, Sabbisetti V, Kaushik S, Sehrawat S, Kulkarni A, Dvorak H, Zetter B, R Edelman E, Sengupta S. Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype. Nature Communications. 6: 8671. PMID 26669454 DOI: 10.1038/Ncomms9671 |
0.345 |
|
| 2015 |
Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu GK, Shenoy AM, Kuriakose MA, ... ... Sengupta S, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nature Communications. 6: 6169. PMID 25721094 DOI: 10.1038/Ncomms7169 |
0.306 |
|
| 2015 |
Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M, Majumder PK, Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nature Communications. 6: 6139. PMID 25669750 DOI: 10.1038/Ncomms7139 |
0.397 |
|
| 2015 |
Babu KG, Majumder B, Thiyagarajan S, Ulaganathan B, Surindran R, Shenoy A, Kuriakose MA, Loda M, Beroukhim R, Horowitz P, Agarwal S, Radhakrishnan P, Sundaram M, Sengupta S, Majumder PK. Application of a robust and novel ex vivo platform mimicking patient heterogenous tumor microenvironment for personalized cancer treatment. Journal of Clinical Oncology. 33: 6029-6029. DOI: 10.1200/Jco.2015.33.15_Suppl.6029 |
0.388 |
|
| 2015 |
Gupta N, Kancharla J, Kaushik S, Hossain S, Sarkar A, Sengupta A, Roy M, Sengupta S. Abstract 649: Supramolecular assembly of antibody-drug conjugates using CORDLink platform for targeted drug delivery Cancer Research. 75: 649-649. DOI: 10.1158/1538-7445.Am2015-649 |
0.413 |
|
| 2015 |
Kulkarni AA, Sabbisetti V, Pandey PR, Sengupta S. Abstract 5522: Combination of a supramolecular nanotherapeutic targeting MEK and immune checkpoint inhibitor exerts a synergistic antitumor outcome Cancer Research. 75: 5522-5522. DOI: 10.1158/1538-7445.Am2015-5522 |
0.457 |
|
| 2015 |
Pandey PR, Sengupta S, Roy S. Abstract 3687: A novel computational platform technology (VOLVOX™) for designing anticancer supramolecular therapeutics Cancer Research. 75: 3687-3687. DOI: 10.1158/1538-7445.Am2015-3687 |
0.414 |
|
| 2014 |
Pandey A, Sarangi S, Chien K, Sengupta P, Papa AL, Basu S, Sengupta S. Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery. Nanotechnology. 25: 445101. PMID 25302488 DOI: 10.1088/0957-4484/25/44/445101 |
0.71 |
|
| 2014 |
Pandey A, Kulkarni A, Roy B, Goldman A, Sarangi S, Sengupta P, Phipps C, Kopparam J, Oh M, Basu S, Kohandel M, Sengupta S. Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy. Cancer Research. 74: 675-85. PMID 24121494 DOI: 10.1158/0008-5472.Can-12-3783 |
0.738 |
|
| 2014 |
Sengupta S. Clinical translational challenges in nanomedicine Mrs Bulletin. 39: 259-264. DOI: 10.1557/Mrs.2014.29 |
0.347 |
|
| 2014 |
Kulkarni AA, Rao P, Goldman A, Sengupta S. Abstract 5419: Computationally-inspired engineering of supramolecular taxane nanoparticles Cancer Research. 74: 5419-5419. DOI: 10.1158/1538-7445.Am2014-5419 |
0.448 |
|
| 2014 |
Roy M, Hossain SS, Sarkar A, Sengupta A, Gupta N, Hussain S, Ansari A, Mylavarapu S, Sengupta S. Abstract 4483: IO125, a novel Pt-based supramolecular therapeutic exhibits increased anti-cancer efficacy compared with oxaliplatin Cancer Research. 74: 4483-4483. DOI: 10.1158/1538-7445.Am2014-4483 |
0.508 |
|
| 2014 |
Connor YD, Tekleab S, Husain A, Walls C, Zetter B, Dvorak H, Sengupta S. Abstract 3600: NanoChannel-mediated communication between tumor cells and endothelium mediates metastatic parasitism Cancer Research. 74: 3600-3600. DOI: 10.1158/1538-7445.Am2014-3600 |
0.422 |
|
| 2014 |
Sarkar SK, Khater Y, Kulkarni A, Sengupta S. Feedback-mediated cancer therapy: a FRET-based nanoreporter approach Proceedings of Spie. 9166: 916607. DOI: 10.1117/12.2061379 |
0.397 |
|
| 2014 |
Kulkarni A, Rao P, Goldman A, Sengupta S. Targeting chemotherapy induced adaptive resistance using hybrid nanoparticles (LB577) The Faseb Journal. 28. DOI: 10.1096/Fasebj.28.1_Supplement.Lb577 |
0.477 |
|
| 2013 |
Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu S, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Research. 73: 6987-97. PMID 24121488 DOI: 10.1158/0008-5472.Can-12-4477 |
0.705 |
|
| 2013 |
Papa AL, Sidiqui A, Balasubramanian SU, Sarangi S, Luchette M, Sengupta S, Harfouche R. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. Cellular Oncology (Dordrecht). 36: 449-57. PMID 24081907 DOI: 10.1007/S13402-013-0146-4 |
0.427 |
|
| 2013 |
Sengupta S, Kulkarni A. Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. Acs Nano. 7: 2878-82. PMID 23607425 DOI: 10.1021/Nn4015399 |
0.41 |
|
| 2013 |
Sarangi S, Pandey A, Papa AL, Sengupta P, Kopparam J, Dadwal U, Basu S, Sengupta S. P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Medical Oncology (Northwood, London, England). 30: 567. PMID 23568163 DOI: 10.1007/S12032-013-0567-Y |
0.693 |
|
| 2012 |
Papa AL, Basu S, Sengupta P, Banerjee D, Sengupta S, Harfouche R. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. Bmc Cancer. 12: 419. PMID 22998550 DOI: 10.1186/1471-2407-12-419 |
0.705 |
|
| 2012 |
Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, Sabbisetti VS, Kopparam J, Kulkarni A, Muto K, Amarasiriwardena C, ... ... Sengupta S, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 109: 11294-9. PMID 22733767 DOI: 10.1073/Pnas.1203129109 |
0.724 |
|
| 2012 |
Paraskar A, Soni S, Roy B, Papa AL, Sengupta S. Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology. 23: 075103. PMID 22275055 DOI: 10.1088/0957-4484/23/7/075103 |
0.425 |
|
| 2012 |
Connor YD, Tekleab S, Gill NK, Bharat D, Lloyd T, Walls CR, Sengupta S. Abstract 4222: Intercellular transfer between metastatic breast cancer and the endothelium mediated by tunneling nanotubes Cancer Research. 72: 4222-4222. DOI: 10.1158/1538-7445.Am2012-4222 |
0.407 |
|
| 2012 |
Roy B, Sengupta P, Soni S, Papa AL, Kopparam J, Sarangi S, Pandey A, Basu S, Sengupta S. Abstract 2892: Enhancing anti cancer activity of PI103, a dual PI3K/mTOR inhibitor, by designing a self assembled Nanoformulation Cancer Research. 72: 2892-2892. DOI: 10.1158/1538-7445.Am2012-2892 |
0.73 |
|
| 2012 |
Goldman AJ, Shunmugam I, Kulkarni A, Rivera F, Sengupta S. Abstract 27: Chemotherapy-induced Akt survival signaling is regulated by CD44- Ezrin/Radaxin Moesin (ERM) scaffolding, dependent on EGFR activity Cancer Research. 72: 27-27. DOI: 10.1158/1538-7445.Am2012-27 |
0.409 |
|
| 2012 |
Roy B, Sengupta P, Dinulescu D, Muto K, Papa AL, Basu S, Sengupta S. Abstract 1951: Targeting cancer by a chimeric nanoparticle formulation of Cisplatin and PI828, a PI3 kinase inhibitor Cancer Research. 72: 1951-1951. DOI: 10.1158/1538-7445.Am2012-1951 |
0.737 |
|
| 2012 |
Kulkarni AA, Soh HX, Sengupta P, Basu S, Sengupta S. Abstract 1945: A novel self assembled taxane nanoparticles for breast cancer chemotherapy Cancer Research. 72: 1945-1945. DOI: 10.1158/1538-7445.Am2012-1945 |
0.728 |
|
| 2011 |
Banerjee D, Sengupta S. Nanoparticles in cancer chemotherapy. Progress in Molecular Biology and Translational Science. 104: 489-507. PMID 22093227 DOI: 10.1016/B978-0-12-416020-0.00012-7 |
0.487 |
|
| 2011 |
Paraskar A, Soni S, Basu S, Amarasiriwardena CJ, Lupoli N, Srivats S, Roy RS, Sengupta S. Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology. 22: 265101. PMID 21576779 DOI: 10.1088/0957-4484/22/26/265101 |
0.696 |
|
| 2011 |
Kohandel M, Haselwandter CA, Kardar M, Sengupta S, Sivaloganathan S. Quantitative model for efficient temporal targeting of tumor cells and neovasculature Computational and Mathematical Methods in Medicine. 2011. PMID 21461349 DOI: 10.1155/2011/790721 |
0.372 |
|
| 2011 |
Banerjee D, Harfouche R, Sengupta S. Nanotechnology-mediated targeting of tumor angiogenesis. Vascular Cell. 3: 3. PMID 21349160 DOI: 10.1186/2045-824X-3-3 |
0.426 |
|
| 2011 |
Sengupta P, Basu S, Sengupta S. Cancer, signal transduction and nanotechnology. Current Drug Delivery. 8: 254-60. PMID 21291374 DOI: 10.2174/156720111795256147 |
0.681 |
|
| 2011 |
Sengupta S, Mantha AK, Mitra S, Bhakat KK. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene. 30: 482-93. PMID 20856196 DOI: 10.1038/Onc.2010.435 |
0.329 |
|
| 2011 |
Pandey A, Oh M, Sengupta S. Abstract 1409: Overexpression of inhibitor of DNA (Id-1) correlates with the invasiveness of colon cancer cells Cancer Research. 71: 1409-1409. DOI: 10.1158/1538-7445.Am2011-1409 |
0.414 |
|
| 2011 |
Pandey A, Roy B, Sarangi S, Sengupta P, Kopparam J, Basu S, Sengupta S. Abstract C187: Posttreatment with PI3-kinase inhibitor enhances the chemotherapeutic effect of cisplatin nanoparticles in breast cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C187 |
0.715 |
|
| 2011 |
Pandey A, Sarangi S, Roy B, Sengupta P, Basu S, Kopparam J, Dadwal UC, Sengupta S. Abstract B221: Clopidogrel augments cisplatin cytotoxicity by enhancing delivery and direct receptor mediated effects. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B221 |
0.718 |
|
| 2010 |
Sinha Roy R, Soni S, Harfouche R, Vasudevan PR, Holmes O, de Jonge H, Rowe A, Paraskar A, Hentschel DM, Chirgadze D, Blundell TL, Gherardi E, Mashelkar RA, Sengupta S. Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 13608-13. PMID 20639469 DOI: 10.1073/Pnas.1006007107 |
0.335 |
|
| 2010 |
Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America. 107: 12435-40. PMID 20616005 DOI: 10.1073/Pnas.1007026107 |
0.477 |
|
| 2010 |
Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S. Shape effect of carbon nanovectors on angiogenesis. Acs Nano. 4: 574-82. PMID 20043662 DOI: 10.1021/Nn901465H |
0.381 |
|
| 2010 |
Chaudhuri P, Soni S, Sengupta S. Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma. Nanotechnology. 21: 025102. PMID 19955607 DOI: 10.1088/0957-4484/21/2/025102 |
0.398 |
|
| 2010 |
Paraskar AS, Soni S, Chaudhuri P, Sengupta S. Abstract 5488: Merging structure-activity relationship and nanotechnology to re-engineer cisplatin Cancer Research. 70: 5488-5488. DOI: 10.1158/1538-7445.Am10-5488 |
0.522 |
|
| 2010 |
Connor Y, Harfouche R, Liu C, Oh M, Sengupta S. Abstract 4813: Modeling interactions between endothelial cells and metastatic breast cancer cells in a three-dimensional culture Cancer Research. 70: 4813-4813. DOI: 10.1158/1538-7445.Am10-4813 |
0.438 |
|
| 2010 |
Harfouche R, Sengupta P, Basu S, Fan J, Sengupta S. Abstract 3706: A novel nanoengineering approach to target pancreatic cancer Cancer Research. 70: 3706-3706. DOI: 10.1158/1538-7445.Am10-3706 |
0.732 |
|
| 2010 |
Soni S, Sengupta S, Paraskar A, Chaudhuri P. Abstract 3520: Pegylated nanoplatinates: A novel re-engineered cisplatin for cancer chemotherapy Cancer Research. 70: 3520-3520. DOI: 10.1158/1538-7445.Am10-3520 |
0.5 |
|
| 2010 |
Sengupta P, Soni S, Basu S, Sengupta S. Abstract 3516: Targeting cancer by cisplatin-containing nanovectors Cancer Research. 70: 3516-3516. DOI: 10.1158/1538-7445.Am10-3516 |
0.724 |
|
| 2010 |
Chaudhuri P, Harfouche R, Sengupta S. The Bittersweet Promise of Glycobiology Biomarkers. 75-88. DOI: 10.1002/9780470918562.Ch5 |
0.306 |
|
| 2009 |
Harfouche R, Hentschel DM, Piecewicz S, Basu S, Print C, Eavarone D, Kiziltepe T, Sasisekharan R, Sengupta S. Glycome and transcriptome regulation of vasculogenesis. Circulation. 120: 1883-92. PMID 19858418 DOI: 10.1161/Circulationaha.108.837724 |
0.614 |
|
| 2009 |
Basu S, Chaudhuri P, Sengupta S. Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle (Georgetown, Tex.). 8: 3480-7. PMID 19823014 DOI: 10.4161/Cc.8.21.9851 |
0.703 |
|
| 2009 |
Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis. 12: 325-38. PMID 19685150 DOI: 10.1007/S10456-009-9154-4 |
0.689 |
|
| 2009 |
Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S. Fullerenol-cytotoxic conjugates for cancer chemotherapy. Acs Nano. 3: 2505-14. PMID 19681636 DOI: 10.1021/Nn900318Y |
0.48 |
|
| 2009 |
Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 106: 7957-61. PMID 19383798 DOI: 10.1073/Pnas.0902857106 |
0.714 |
|
| 2007 |
Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer British Journal of Cancer. 96: 1315-1319. PMID 17406364 DOI: 10.1038/Sj.Bjc.6603707 |
0.453 |
|
| 2007 |
Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S. Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis. 28: 81-92. PMID 16777988 DOI: 10.1093/Carcin/Bgl100 |
0.346 |
|
| 2007 |
Harfouche R, Hussain SN, Rabbani SA, Sengupta S. Regulation of breast cancer extravasation by Angiopoietin‐1 The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A254-B |
0.361 |
|
| 2006 |
Chakrabarti S, Sengupta S, Sengupta A, Basak SN, Roy A, Panda C, Roychoudhury S. Genomic instabilities in squamous cell carcinoma of head and neck from the Indian population. Molecular Carcinogenesis. 45: 270-7. PMID 16402388 DOI: 10.1002/Mc.20178 |
0.328 |
|
| 2005 |
Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 436: 568-72. PMID 16049491 DOI: 10.1038/Nature03794 |
0.419 |
|
| 2005 |
Sengupta S, Roychoudhury S. DNA Double Strand Break and Repair: Mechanisms and Involvement in Human Cancer International Journal of Human Genetics. 5: 1-10. DOI: 10.1080/09723757.2005.11885909 |
0.307 |
|
| 2004 |
Sengupta S, Kiziltepe T, Sasisekharan R. A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 1565-7. PMID 15333517 DOI: 10.1096/Fj.04-1934Fje |
0.328 |
|
| 2003 |
Sengupta S, Sellers LA, Li RC, Gherardi E, Zhao G, Watson N, Sasisekharan R, Fan TP. Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation. 107: 2955-61. PMID 12782568 DOI: 10.1161/01.Cir.0000077501.19266.E5 |
0.344 |
|
| 2003 |
Sengupta S, Sellers LA, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. British Journal of Pharmacology. 139: 219-31. PMID 12770927 DOI: 10.1038/Sj.Bjp.0705216 |
0.343 |
|
| Show low-probability matches. |